[Form 4] Thermo Fisher Scientific, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Thermo Fisher Scientific (TMO) — Form 4 insider transaction

Executive Vice President Gianluca Pettiti reported the sale of 400 common shares on 07/25/2025 at $479.98 per share, generating roughly $0.19 million in proceeds. The trade was executed under a Rule 10b5-1 plan that Pettiti adopted on 02/10/2025, indicating it was pre-scheduled and not based on current market conditions.

Post-transaction, the executive directly owns 22,366.925 shares. No derivative securities were bought or sold and no indirect holdings were reported. The filing discloses no additional company fundamentals or other insider activity.

• Transaction size is modest relative to Pettiti’s remaining stake, suggesting continued alignment with shareholders.
• No impact on share count or control structure; purely a personal liquidity event.

Positive

• Pre-planned 10b5-1 sale reduces risk of informational trading and signals routine liquidity management.
• Executive retains 22,366.925 shares, maintaining significant equity alignment with shareholders.

Negative

• Insider selling can be interpreted as reduced short-term confidence, though scale is small.

Insights

Securities Analyst

TL;DR: Small, pre-planned insider sale; neutral corporate signal.

The 400-share sale equals about 1.8% of Pettiti’s reported direct holdings and was executed under a 10b5-1 plan, limiting informational value. Proceeds (~$192k) are immaterial to Thermo Fisher’s market capitalization and do not alter ownership structure. Because no other insiders transacted and no derivative positions changed, I view the filing as neutral for investors: it neither confirms bullish conviction nor implies adverse developments. Monitoring cumulative insider activity remains advisable.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Pettiti Gianluca

(Last) (First) (Middle)

168 THIRD AVENUE

(Street)

WALTHAM MA 02451

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
THERMO FISHER SCIENTIFIC INC. [ TMO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Vice President

3. Date of Earliest Transaction (Month/Day/Year)
07/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/25/2025		S(1)		400	D	$479.98	22,366.925	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 10, 2025.

	/s/ Melodie T. Morin, Attorney-in-Fact for Gianluca Pettiti	07/28/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many TMO shares did EVP Gianluca Pettiti sell?

He sold 400 common shares.

At what price were the Thermo Fisher shares sold?

The shares were sold at $479.98 each.

What is the executive's remaining ownership after the sale?

Pettiti now directly owns 22,366.925 shares.

Was the TMO insider transaction part of a 10b5-1 plan?

Yes. The sale was executed under a Rule 10b5-1 trading plan adopted on 02/10/2025.

Does the Form 4 report any derivative security activity?

No. No derivative securities were acquired or disposed of in this filing.